Bailard’s Cardiff Oncology CRDF Stock Holding History

Bailard’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27,000	Closed	-$162K	–	743
2021 Q4	$162K	Sell	27,000 -2,200	-8%	-$13.1K	0.01%	700
2021 Q3	$194K	Buy	29,200 +14,800	+103%	+$93K	0.01%	686
2021 Q2	$96K	Buy	+14,400	New	+$122K	﹤0.01%	697

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's CRDF Position: Q1 2022 in Review

Bailard sold out of Cardiff Oncology (CRDF) in Q1 2022, closing a stake of 27,000 shares — an estimated $162K sold.

Bailard first reported a position in CRDF in Q2 2021 and held it in 3 quarters. The position peaked at $194K in Q3 2021. 91 funds tracked by Wall St. Rank hold CRDF as of Q1 2022.

Bailard reported no remaining Cardiff Oncology position as of Q1 2022 after selling out during the quarter.
Bailard sold 27,000 Cardiff Oncology shares in Q1 2022, an estimated $162K.
Bailard first reported a position in Cardiff Oncology in Q2 2021 and held it in 3 quarters.
Bailard's Cardiff Oncology position peaked at $194K in Q3 2021.
91 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.